A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system

A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system

Background: Everolimus is an inhibitor of the mammalian target of rapamycin and is used to treat various tumors. The presented study aimed to evaluate the Everolimus-associated adverse events (AEs) through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS).Meth...

Full description

Bibliographic Details
Main Authors: Bin Zhao, Yumei Fu, Shichao Cui, Xiangning Chen, Shu Liu, Lan Luo
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Pharmacology
Subjects:
Everolimus
data mining
FAERS
pharmacovigilance
adverse event
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1333662/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1333662/full

Similar Items